Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about NanoViricides, Inc.
NanoViricides, Inc. News
NanoViricides, Inc. Quantitative Score
About NanoViricides, Inc.
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
NanoViricides, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
NanoViricides, Inc. Financials
Table Compare
Compare NNVC metrics with: | |||
|---|---|---|---|
Earnings & Growth | NNVC | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | NNVC | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | NNVC | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | NNVC | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
NanoViricides, Inc. Income
NanoViricides, Inc. Balance Sheet
NanoViricides, Inc. Cash Flow
NanoViricides, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
NanoViricides, Inc. Executives
| Name | Role |
|---|---|
| Dr. Anil R. Diwan Ph.D. | Executive Chairman, President, Chief Executive Officer & Secretary |
| Ms. Meeta R. Vyas B.S., M.B.A., MBA, SB | Chief Financial Officer & Compliance Officer |
| Dr. Randall W. Barton Ph.D. | Chief Scientific Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Anil R. Diwan Ph.D. | Executive Chairman, President, Chief Executive Officer & Secretary | 1959 | 400K | |
| Ms. Meeta R. Vyas B.S., M.B.A., MBA, SB | Chief Financial Officer & Compliance Officer | Female | 1959 | 129.6K |
| Dr. Randall W. Barton Ph.D. | Chief Scientific Officer | 1947 | -- |
NanoViricides, Inc. Insider Trades
| Date | 21 Feb |
| Name | BONIUK MILTON |
| Role | |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 21 Feb |
| Name | Stephenson Fournier, PLLC |
| Role | |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 8 Aug |
| Name | Diwan Anil |
| Role | President |
| Transaction | Disposed |
| Type | G-Gift |
| Shares | 94471 |
| Date | 7 Feb |
| Name | Jawadakar Makarand |
| Role | Director |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 2 Jun |
| Name | Day Mark D. |
| Role | Director |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 21 Feb | BONIUK MILTON | Disposed | 0 | ||
| 21 Feb | Stephenson Fournier, PLLC | Disposed | 0 | ||
| 8 Aug | Diwan Anil | President | Disposed | G-Gift | 94471 |
| 7 Feb | Jawadakar Makarand | Director | Disposed | 0 | |
| 2 Jun | Day Mark D. | Director | Disposed | 0 |